Tofacitinib Citrate(CAS 540737-29-9)Inflammation reduction API

$300.00

Tofacitinib citrate (marketed as Xeljanz) is an oral Janus kinase (JAK) inhibitor used to treat autoimmune conditions like rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and ankylosing spondylitis.

Category:

Tofacitinib Citrate is an oral, small-molecule inhibitor that target-blocks the Janus kinase (JAK) pathway. By disrupting the signaling network of inflammatory cytokines, it effectively dampens the overactive immune responses responsible for chronic autoimmune conditions.

Reviews

There are no reviews yet.

Be the first to review “Tofacitinib Citrate(CAS 540737-29-9)Inflammation reduction API”

Your email address will not be published. Required fields are marked *